Back to results
US 12,213,988 B2Granted
Methods of treating chronic kidney disease with dapagliflozin
AssigneeAstraZeneca AB
InventorAnna Maria Langkilde
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Claims24
A method for treating a patient with chronic kidney disease at risk of progression, the method comprising:
- administering dapagliflozin once daily to the patient at a dose and duration sufficient to reduce the patient's risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure;
- wherein the patient does not have type II diabetes;
- and
- wherein the duration is at least four months.
1 more element
A method for treating a patient with chronic kidney disease at risk of progression, the method comprising:
- administering dapagliflozin once daily to the patient at a dose and duration sufficient to reduce a risk of an incidence of a composite endpoint;
- wherein the patient does not have type II diabetes;
- wherein the composite endpoint is ˜50% sustained decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease (ESKD), and CV or renal death;
- and
- wherein the duration is at least four months.
2 more elements
Dependencies are inferred from the claim text.